GI
BHVN

GAMCO Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

GAMCO Investors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,350
Closed -$4.13M – 954
2022
Q3 		$4.13M Buy
27,350
+7,138
+35% +$1.06M 0.05% 334
2022
Q2 		$2.94M Buy
+20,212
New +$2.58M 0.03% 406

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

GAMCO Investors's BHVN Position: Q4 2022 in Review

GAMCO Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 27,350 shares — an estimated $4.13M sold.

GAMCO Investors first reported a position in BHVN in Q2 2022 and held it in 2 quarters. The position peaked at $4.13M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • GAMCO Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • GAMCO Investors sold 27,350 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $4.13M.
  • GAMCO Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022 and held it in 2 quarters.
  • GAMCO Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $4.13M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on GAMCO Investors's 13F filing for Q4 2022, filed 13 Feb 2023.